Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide
暂无分享,去创建一个
[1] W. Feuer,et al. Ocular Decompression With Cotton Swabs Lowers Intraocular Pressure Elevation After Intravitreal Injection , 2014, Journal of glaucoma.
[2] A. Messias,et al. Comparison of Acetazolamide, Brimonidine, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Initial Intravitreal Bevacizumab Injection: A Randomized Clinical Trial , 2014, Journal of glaucoma.
[3] D. Denis,et al. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. , 2014, International journal of ophthalmology.
[4] Paul P. Lee,et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. , 2014, Ophthalmology.
[5] D. Moshfeghi,et al. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. , 2013, Ophthalmic surgery, lasers & imaging retina.
[6] Zhangwei Yang,et al. Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials , 2013, Clinical Drug Investigation.
[7] G. Sobacı,et al. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. , 2013, International journal of ophthalmology.
[8] Douglas J. Rhee,et al. Soluble Guanylate Cyclase α1–Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma , 2013, PloS one.
[9] S. Wolf,et al. Long-Term Intraocular Pressure Changes in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab , 2013, Ophthalmologica.
[10] J. Yoo,et al. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol Prophylaxis on Intravitreal Anti-VEGF Injection-Induced Intraocular Hypertension , 2013, Seminars in ophthalmology.
[11] J. R. Ferencz,et al. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. , 2013, The Israel Medical Association journal : IMAJ.
[12] Jesse J. Jung,et al. CLINICAL PREDICTORS OF SUSTAINED INTRAOCULAR PRESSURE ELEVATION DUE TO INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2013, Retina.
[13] P. Kruzliak,et al. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension , 2012, Angiogenesis.
[14] B. Swalduz,et al. Efficacité d’un traitement prophylactique hypotonisant dans l’hypertonie oculaire induite après injections intravitréennes , 2012 .
[15] J. García-Feijóo,et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. , 2012, Investigative ophthalmology & visual science.
[16] Ursula Schmidt-Erfurth,et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.
[17] S. Skalicky,et al. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. , 2012, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[18] M. Pistilli,et al. A LACK OF DELAYED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS TREATED WITH INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB , 2012, Retina.
[19] J. Välimäki,et al. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: A Prospective Study , 2012, Acta ophthalmologica.
[20] J. Sorenson,et al. Sustained Increased Intraocular Pressure Related to Intravitreal Antivascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration , 2012, Journal of glaucoma.
[21] I. Lavi,et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.
[22] Jesse J. Jung,et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. , 2012, Ophthalmology.
[23] C. Dot,et al. [Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections]. , 2012, Journal francais d'ophtalmologie.
[24] E. Ongini,et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. , 2011, Experimental eye research.
[25] Andrea Scozzafava,et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. , 2011, Bioorganic & medicinal chemistry letters.
[26] D. Sarraf,et al. SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIB , 2011, Retina.
[27] L. Kodjikian,et al. "High-molecular-weight aggregates in repackaged bevacizumab". , 2011, Retina.
[28] M. Apostolopoulos,et al. Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab , 2011, International Ophthalmology.
[29] R. Frenkel,et al. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. , 2010, Archives of ophthalmology.
[30] T. Choueiri,et al. Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors , 2010, Hypertension.
[31] N. Sharif,et al. Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling. , 2010, Investigative ophthalmology & visual science.
[32] Michael B Horsley,et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. , 2010, American journal of ophthalmology.
[33] M. Kahook,et al. In Vitro Effects of Antivascular Endothelial Growth Factors on Cultured Human Trabecular Meshwork Cells , 2010, Journal of glaucoma.
[34] M. Kahook,et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents , 2010, British Journal of Ophthalmology.
[35] M. Kahook,et al. Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis , 2010, The open ophthalmology journal.
[36] A. Mirshahi,et al. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.
[37] P. Theoulakis,et al. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. , 2010, Klinische Monatsblatter fur Augenheilkunde.
[38] R. Adelman,et al. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[39] A. Mirshahi,et al. Course of Intraocular Pressure after Intravitreal Injection of 0.05 mL Ranibizumab (Lucentis®) , 2010, European journal of ophthalmology.
[40] M. L. Salvetat,et al. Short-term Effect of Intravitreal Injection of Ranibizumab (Lucentis) on Intraocular Pressure , 2009, Journal of glaucoma.
[41] Kihwang Lee,et al. A PROSPECTIVE STUDY OF BLOOD PRESSURE AND INTRAOCULAR PRESSURE CHANGES IN HYPERTENSIVE AND NONHYPERTENSIVE PATIENTS AFTER INTRAVITREAL BEVACIZUMAB INJECTION , 2009, Retina.
[42] R. Adelman,et al. ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS , 2009, Retina.
[43] M. Kahook,et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. , 2009, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[44] D. Ellis,et al. Characterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshwork. , 2009, Investigative ophthalmology & visual science.
[45] J. Pulido,et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab , 2007, Eye.
[46] Judy E. Kim,et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. , 2008, American journal of ophthalmology.
[47] D. Ellis,et al. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. , 2008, American journal of physiology. Cell physiology.
[48] A. Edwards,et al. Persisent ocular hypertension following intravitreal ranibizumab , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.
[49] M. Maier,et al. Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma. , 2008, American journal of ophthalmology.
[50] H. Hollands,et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[51] W. Freeman,et al. CHANGES OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) , 2007, Retina.
[52] H. Izzedine,et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[53] A. Neubauer,et al. Bevacizumab wirkt nicht toxisch auf Zellen des menschlichen Auge , 2007, Der Ophthalmologe.
[54] M. Maier,et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. , 2007, Acta ophthalmologica Scandinavica.
[55] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[56] A. Kampik,et al. [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]. , 2007, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.
[57] G. Shah,et al. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. , 2006, American journal of ophthalmology.
[58] M. Wiederholt,et al. Regulation of Trabecular Meshwork Contractility , 2000, Ophthalmologica.
[59] U. Schlötzer-Schrehardt,et al. Localization of nitric oxide synthase isoforms in porcine ocular tissues. , 1999, Current eye research.
[60] H. Granger,et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. , 1998, American journal of physiology. Heart and circulatory physiology.
[61] J. Nathanson,et al. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. , 1995, Investigative ophthalmology & visual science.
[62] J. Nathanson,et al. Alterations of ocular nitric oxide synthase in human glaucoma. , 1995, Investigative ophthalmology & visual science.
[63] M. Wiederholt,et al. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. , 1994, Investigative ophthalmology & visual science.